MX2021016098A - Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. - Google Patents
Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.Info
- Publication number
- MX2021016098A MX2021016098A MX2021016098A MX2021016098A MX2021016098A MX 2021016098 A MX2021016098 A MX 2021016098A MX 2021016098 A MX2021016098 A MX 2021016098A MX 2021016098 A MX2021016098 A MX 2021016098A MX 2021016098 A MX2021016098 A MX 2021016098A
- Authority
- MX
- Mexico
- Prior art keywords
- molecules
- antibodies against
- humanized antibodies
- humanized antibody
- antibody molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962862457P | 2019-06-17 | 2019-06-17 | |
| US202063035323P | 2020-06-05 | 2020-06-05 | |
| PCT/US2020/038143 WO2020257289A2 (en) | 2019-06-17 | 2020-06-17 | Humanized antibody molecules to cd138 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021016098A true MX2021016098A (es) | 2022-02-03 |
Family
ID=71995040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021016098A MX2021016098A (es) | 2019-06-17 | 2020-06-17 | Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12338291B2 (enExample) |
| EP (1) | EP3983442A2 (enExample) |
| JP (1) | JP7716342B2 (enExample) |
| KR (1) | KR20220044939A (enExample) |
| CN (1) | CN114269786B (enExample) |
| AU (1) | AU2020294696A1 (enExample) |
| BR (1) | BR112021025421A2 (enExample) |
| CA (1) | CA3142021A1 (enExample) |
| IL (1) | IL289034A (enExample) |
| MX (1) | MX2021016098A (enExample) |
| MY (1) | MY210065A (enExample) |
| PH (1) | PH12021553109A1 (enExample) |
| TW (1) | TW202112822A (enExample) |
| WO (1) | WO2020257289A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY205689A (en) | 2017-10-02 | 2024-11-06 | Visterra Inc | Antibody molecules to cd138 and uses thereof |
| CA3142021A1 (en) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| EP4363855A4 (en) * | 2021-06-29 | 2025-04-16 | Sheba Impact Ltd. | DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER |
| WO2023097254A1 (en) * | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
| US20250064933A1 (en) * | 2021-12-30 | 2025-02-27 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors comprising a pdz binding motif |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8905669D0 (en) | 1989-03-13 | 1989-04-26 | Celltech Ltd | Modified antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69133557D1 (de) | 1990-08-29 | 2007-03-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| DE69233769D1 (de) | 1991-03-01 | 2009-09-24 | Dyax Corp | Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon |
| AU662148B2 (en) | 1991-04-10 | 1995-08-24 | Scripps Research Institute, The | Heterodimeric receptor libraries using phagemids |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| WO2001098539A2 (en) * | 2000-06-21 | 2001-12-27 | Hitachi Chemical Co., Ltd. | Gene markers for lung cancer |
| US20060045877A1 (en) | 2004-08-30 | 2006-03-02 | Goldmakher Viktor S | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
| EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
| US20070054332A1 (en) | 2005-08-10 | 2007-03-08 | Alan Rapraeger | Syndecan 1 ectodomain inhibits cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2238169A1 (en) | 2007-12-26 | 2010-10-13 | Biotest AG | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
| HRP20140604T1 (hr) | 2007-12-26 | 2014-09-12 | Biotest Ag | Sredstva koja djeluju na cd138 i njihova upotreba |
| JP5817034B2 (ja) | 2007-12-26 | 2015-11-18 | バイオテスト・アクチエンゲゼルシヤフト | Ｃｄ１３８を標的とする免疫複合体及びその使用 |
| BRPI0821417A2 (pt) | 2007-12-26 | 2015-06-16 | Biotest Ag | Método para diminuir a adesão de células de estroma a células tumorais que expressam cd138 em células tumorais de um indivíduo em necessidade do mesmo |
| BRPI1013990A2 (pt) | 2009-05-06 | 2019-04-30 | Biotest Ag | método para tratar uma doença , e, combinação anticâncer |
| US9249467B2 (en) | 2011-09-16 | 2016-02-02 | Steven Goodison | Bladder cancer detection composition, kit and associated methods |
| US10577543B2 (en) | 2011-10-27 | 2020-03-03 | Raymond Roger Wallage | Efficient oil shale recovery method |
| SG11201402887SA (en) | 2011-12-08 | 2014-07-30 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
| AU2013229786B2 (en) | 2012-03-08 | 2017-06-22 | Halozyme, Inc. | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof |
| GB201216002D0 (en) | 2012-09-07 | 2012-10-24 | Deutsches Rheuma Forschungszentrum Berlin Drfz | Compositions adn methods |
| WO2014089354A1 (en) | 2012-12-07 | 2014-06-12 | The Regents Of The University Of California | Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| CN103103197A (zh) | 2013-01-30 | 2013-05-15 | 百奇生物科技（苏州）有限公司 | 抗cd138单克隆抗体可变区序列及其制备方法和应用 |
| RU2611685C2 (ru) * | 2015-07-20 | 2017-02-28 | Илья Владимирович Духовлинов | Гуманизированное моноклональное антитело, специфичное к синдекану-1 |
| FI3494134T3 (fi) | 2016-08-02 | 2026-02-19 | Visterra Inc | Muunneltuja polypeptidejä ja niiden käyttötapoja |
| EP3615573A4 (en) | 2017-04-26 | 2021-01-20 | Mitsubishi Tanabe Pharma Corporation | SYNDECAN-1 (CD138) BINDING AGENTS AND THEIR USES |
| MY205689A (en) * | 2017-10-02 | 2024-11-06 | Visterra Inc | Antibody molecules to cd138 and uses thereof |
| US12172986B2 (en) | 2018-06-01 | 2024-12-24 | Eisai R&D Management Co., Ltd | Splicing modulator antibody-drug conjugates and methods of use |
| SG11202111330XA (en) | 2019-06-07 | 2021-12-30 | Adimab Llc | Engineered ph-dependent anti-cd3 antibodies, and methods for their generation and use |
| CA3142021A1 (en) | 2019-06-17 | 2020-12-24 | Visterra, Inc. | Humanized antibody molecules to cd138 and uses thereof |
| US12590171B2 (en) * | 2019-09-27 | 2026-03-31 | Nanjing GenScript Biotech Co., Ltd. | Anti-VHH domain antibodies and use thereof |
| WO2023097254A1 (en) | 2021-11-24 | 2023-06-01 | Visterra, Inc. | Engineered antibody molecules to cd138 and uses thereof |
-
2020
- 2020-06-17 CA CA3142021A patent/CA3142021A1/en active Pending
- 2020-06-17 JP JP2021574798A patent/JP7716342B2/ja active Active
- 2020-06-17 EP EP20753497.5A patent/EP3983442A2/en active Pending
- 2020-06-17 US US16/904,090 patent/US12338291B2/en active Active
- 2020-06-17 KR KR1020227001161A patent/KR20220044939A/ko active Pending
- 2020-06-17 MX MX2021016098A patent/MX2021016098A/es unknown
- 2020-06-17 PH PH1/2021/553109A patent/PH12021553109A1/en unknown
- 2020-06-17 TW TW109120450A patent/TW202112822A/zh unknown
- 2020-06-17 WO PCT/US2020/038143 patent/WO2020257289A2/en not_active Ceased
- 2020-06-17 MY MYPI2021007210A patent/MY210065A/en unknown
- 2020-06-17 BR BR112021025421A patent/BR112021025421A2/pt unknown
- 2020-06-17 CN CN202080058059.XA patent/CN114269786B/zh active Active
- 2020-06-17 AU AU2020294696A patent/AU2020294696A1/en active Pending
-
2021
- 2021-12-15 IL IL289034A patent/IL289034A/en unknown
-
2025
- 2025-05-21 US US19/214,961 patent/US20250382379A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020257289A2 (en) | 2020-12-24 |
| PH12021553109A1 (en) | 2022-08-01 |
| JP7716342B2 (ja) | 2025-07-31 |
| US20200392241A1 (en) | 2020-12-17 |
| CN114269786A (zh) | 2022-04-01 |
| CA3142021A1 (en) | 2020-12-24 |
| KR20220044939A (ko) | 2022-04-12 |
| MY210065A (en) | 2025-08-25 |
| US12338291B2 (en) | 2025-06-24 |
| US20250382379A1 (en) | 2025-12-18 |
| TW202112822A (zh) | 2021-04-01 |
| AU2020294696A1 (en) | 2022-01-20 |
| IL289034A (en) | 2022-02-01 |
| JP2022537289A (ja) | 2022-08-25 |
| EP3983442A2 (en) | 2022-04-20 |
| CN114269786B (zh) | 2026-03-10 |
| BR112021025421A2 (pt) | 2022-02-01 |
| WO2020257289A3 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003783A (es) | Moleculas de anticuerpo de cd138 y sus usos. | |
| CR20230477A (es) | MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593) | |
| CO2021006869A2 (es) | Anticuerpos humanizados contra c-kit | |
| CO2018006461A2 (es) | Moléculas de anticuerpo contra april y usos de las mismas | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| MX2021002690A (es) | Anticuerpos anti-avb8 y composiciones y usos de los mismos. | |
| CL2017000888A1 (es) | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas | |
| UY35967A (es) | Moléculas de anticuerpo que se unen a pd-1 y usos de las mismas | |
| MX2018007423A (es) | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. | |
| CO2017008482A2 (es) | Anticuerpos anti-transtiretina | |
| CO2017008476A2 (es) | Anticuerpos anti-transtiretina | |
| BR112021025421A2 (pt) | Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos | |
| CO2019011458A2 (es) | Anticuerpo monoclonal para pd-l1 | |
| CL2020000920A1 (es) | Anticuerpo monoclonal anti-il-5ra. | |
| CO2021000349A2 (es) | Moléculas de anticuerpo de componente de complemento 5 y sus usos | |
| EA202090891A1 (ru) | Молекулы антител против cd138 и их применение | |
| AR119639A1 (es) | Moléculas de anticuerpo para cd73 y sus usos | |
| AR104081A1 (es) | Moléculas de anticuerpo que se unen a pd-l1 y sus usos |